Trephine
AboutSpecialtiesPricingLoading...

Copyright © 2024 Trephine. All rights reserved. The content of this site is intended for health care professionals.

TREPHINE

Terms Of UsePrivacy Policy

Blood advancesComparative Study

08 Jul 2025

Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-matched donors is the gold standard. However, haploidentical stem cell transplantation using posttransplant cyclophosphamide (PTCY-haplo) and cord blood transplants (CBTs) are alternatives when HLA-matched donors are not available.

Using Japanese registry data, we evaluated the impact of haploidentical donor age on posttransplant outcomes by comparing PTCY-haplo and CBT.

We analyzed data for 5161 patients aged 16 to 70 years who received their first HSCT for acute leukemia, myelodysplastic syndrome, or chronic myeloid leukemia.

Haploidentical donors were categorized as "younger" (aged <40 years) or "older" (aged ≥40 years), and the patients were divided into younger (aged <50 years) and older (aged ≥50 years) cohorts. In the older cohort, PTCY-haplo from younger donors had better overall survival (OS; 55. 5% vs 50.

8%, P = . 006), lower nonrelapse mortality (NRM; 17. 3% vs 28. 6%, P < . 001), and higher relapse rates (33. 0% vs 24. 9%, P = . 017) than with CBT. PTCY-haplo from older donors had comparable OS (44. 1% vs 50. 8%, P = 1. 00), NRM (27. 3% vs 28. 6%, P = 1. 00), and relapse (29. 2% vs 24. 9%, P = .

90) to that with CBT. In the younger cohort, PTCY-haplo from younger and older donors showed OS, NRM, and relapse comparable with CBT. In the older cohort, cumulative incidence of acute graft-versus-host disease (GVHD) was higher with CBT than with PTCY-haplo, regardless of donor age.

However, in the younger cohort, acute GVHD was lower in PTCY-haplo from younger donors than with CBT. PTCY-haplo from younger donors to older patients offers better clinical outcomes than CBT.

CommentIn

Blood Adv. 2025 Jul 8;9(13):3308-3309. doi: 10.1182/bloodadvances.2025016335.

Article info

Journal issue:

  • Volume: 9
  • Issue: 13

Doi:

10.1182/bloodadvances.2024014938

More resources:

Elsevier Science

Full Text Sources

Paid

MedlinePlus Health Information

Medical

Free resource

NCI CPTC Antibody Characterization Program

Research Materials

Free resource

ClinicalKey

Full Text Sources

Paid

Silverchair Information Systems

Full Text Sources

Paid

Share: